Ozempic is frequently denied by insurance because it is FDA-approved only for type 2 diabetes, not for weight loss. If you were prescribed it for weight management, your plan likely excludes that use entirely. Even with a diabetes diagnosis, many insurers require you to try cheaper medications first or submit extensive paperwork before they’ll approve it. The specific reason for your denial depends on your insurance type, your diagnosis, and your plan’s formulary rules.
The FDA Label Is the Root of the Problem
Ozempic (semaglutide) has two FDA-approved uses: improving blood sugar control in adults with type 2 diabetes, and reducing the risk of heart attack, stroke, or cardiovascular death in adults with type 2 diabetes and established heart disease. That’s it. It is not approved for weight loss.
Wegovy, made by the same company and containing the same active ingredient at a higher dose, is the version approved for chronic weight management. Insurance companies treat these as entirely different drugs because they carry different FDA labels. When your doctor prescribes Ozempic for weight loss, the insurer sees an “off-label” use and will almost certainly deny coverage. This single distinction is the most common reason people get rejected.
Medicare Cannot Cover It for Weight Loss
If you’re on Medicare, federal law is the barrier. The Social Security Act specifically excludes “agents when used for anorexia, weight loss, or weight gain” from the Part D prescription drug benefit. This isn’t a policy choice by your Medicare plan. It’s a statutory prohibition that applies to all Medicare Part D coverage nationwide. No appeal or exception request can override it when the prescription is for weight management.
Medicare does cover Ozempic for type 2 diabetes, but access has tightened dramatically. Prior authorization was required for 5% or fewer of Medicare beneficiaries until 2024. By 2025, it was required for nearly 100%. Researchers at Penn’s Leonard Davis Institute attribute this spike to insurers trying to prevent off-label weight loss prescribing under the diabetes label.
Most Employer Plans Exclude Weight Loss Coverage
If you get insurance through your job, the odds aren’t great either. According to a 2025 KFF survey, only 19% of large firms (200 or more workers) cover GLP-1 drugs like Ozempic when used primarily for weight loss. The breakdown by company size tells the story clearly:
- Companies with 200 to 999 workers: 16% cover GLP-1s for weight loss, 58% explicitly exclude them
- Companies with 1,000 to 4,999 workers: 30% cover, 57% exclude
- Companies with 5,000+ workers: 43% cover, 49% exclude
Even at the largest employers, fewer than half offer coverage. Many companies that once covered these drugs have pulled back as costs rose, and those that still offer coverage typically layer on restrictions like prior authorization and quantity limits.
Medicaid Coverage Varies by State
State Medicaid programs are required to cover Ozempic for diabetes, since it’s FDA-approved for that condition. But coverage for weight loss is optional, and most states don’t offer it. As of January 2026, only 13 state Medicaid programs cover GLP-1 drugs for obesity treatment under their fee-for-service plans. The same federal statute that blocks Medicare from covering weight loss drugs gives states the choice to exclude them from Medicaid too.
Even in states that do cover weight loss medications through Medicaid, the prior authorization requirements tend to be stricter than what the FDA label actually calls for. A review of state policies found that 70% specified which health conditions you must have alongside obesity, and some required at least two additional conditions, while the FDA label only requires one unspecified health risk.
Step Therapy and Prior Authorization for Diabetes
Having a type 2 diabetes diagnosis doesn’t guarantee smooth coverage. Most insurers require step therapy, meaning you must try and fail on cheaper medications before they’ll pay for Ozempic. The most common first step is metformin, a generic drug that costs a fraction of Ozempic’s price. You typically need to show that metformin didn’t control your blood sugar adequately, caused side effects you couldn’t tolerate, or is medically contraindicated for you.
Some plans go further. The VA’s criteria, which mirror many commercial insurers’ approach, require that patients also be evaluated for another diabetes drug (empagliflozin) before Ozempic is approved. The logic is that Ozempic should be reserved for people whose blood sugar goals aren’t met with maximally tolerated doses of these cheaper alternatives. In clinical trials, adding semaglutide to oral medications lowered A1C by 1.3% to 1.5%, so insurers generally want to see that this level of improvement is actually needed based on your current numbers.
How to Request a Coverage Exception
If your claim was denied, you have the right to request an exception. The process requires your prescribing doctor to submit a supporting statement explaining why the alternatives on your plan’s formulary would be less effective for your specific situation or would cause adverse effects. This statement can be submitted verbally at first, though most plans will ask for written follow-up.
For a formulary exception (when the drug isn’t on your plan’s approved list at all), your doctor needs to explain why every covered alternative is inadequate for you. For a tiering exception (when Ozempic is covered but placed on an expensive tier), the argument is narrower: your doctor must show that the cheaper preferred drugs wouldn’t work as well or would harm you. There’s no required form. Your doctor can use a letter, a plan-specific form, or a standard coverage determination request.
The strength of your case depends on documentation. If you’ve already tried and failed metformin or other first-line treatments, keep records of those trials, including how long you were on each medication, what your A1C levels were before and after, and what side effects you experienced. A clear paper trail of failed alternatives is the single most persuasive element in an appeal.
Manufacturer Savings Cards Have Limits
Novo Nordisk, the maker of Ozempic, offers a savings card that brings your cost down to as little as $25 per month for up to three months, with a maximum savings of $100 per month. But there are significant eligibility restrictions. You must have commercial insurance. If you’re on Medicare, Medicaid, VA, TRICARE, or any other government-funded plan, you’re disqualified. People who have both commercial and government coverage are also excluded.
There’s one exception worth noting: Federal Employees Health Benefits (FEHB) plans, Affordable Care Act marketplace plans, and state employee plans are not considered government programs for purposes of the savings card. If your coverage comes through one of those, you may still qualify. The savings card is a short-term bridge, not a long-term solution, but it can help while you work through the prior authorization or appeals process with your insurer.